Terms: = Endocrine gland cancer AND MYD88, Q99836, MYD88D, 4615 AND Treatment
33 results:
1. Genomic landscape and distinct molecular subtypes of primary testicular lymphoma.
Zhang W; Yang P; Yang Y; Liu S; Xu Y; Wu C; Wang J; Liu C; Liu H; Li S; Huang W; Jing H
J Transl Med; 2024 May; 22(1):414. PubMed ID: 38693538
[TBL] [Abstract] [Full Text] [Related]
2. P53 and TLR4 expression are prognostic markers informing progression free survival of advanced stage high grade serous ovarian cancer.
Bates M; Mullen D; Lee E; Costigan D; Heron EA; Kernan N; Barry-O'Crowley J; Martin C; Keegan H; Malone V; Brooks RD; Brooks DA; Logan JM; Martini C; Selemidis S; McFadden J; O'Riain C; Spillane CD; Gallagher MF; McCann A; O'Toole S; O'Leary JJ
Pathol Res Pract; 2024 Jan; 253():155020. PubMed ID: 38103365
[TBL] [Abstract] [Full Text] [Related]
3. PAUF Induces Migration of Human Pancreatic cancer Cells Exclusively via the TLR4/myd88/NF-κB Signaling Pathway.
Youn SE; Jiang F; Won HY; Hong DE; Kang TH; Park YY; Koh SS
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232715
[TBL] [Abstract] [Full Text] [Related]
4. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/myd88/AKT/NF-κB pathway in pancreatic cancer.
Yin H; Pu N; Chen Q; Zhang J; Zhao G; Xu X; Wang D; Kuang T; Jin D; Lou W; Wu W
Cell Death Dis; 2021 Oct; 12(11):1033. PubMed ID: 34718325
[TBL] [Abstract] [Full Text] [Related]
5. The role of the MAD2-TLR4-myd88 axis in paclitaxel resistance in ovarian cancer.
Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
[TBL] [Abstract] [Full Text] [Related]
6. Morphologic Patterns and the Correlation With myd88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.
Chen Z; Zou Y; Liu W; Guan P; Tao Q; Xiang C; Zhang W; Ye Y; Yan J; Zhao S
Am J Surg Pathol; 2020 Apr; 44(4):444-455. PubMed ID: 31609782
[TBL] [Abstract] [Full Text] [Related]
7. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract] [Full Text] [Related]
8. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract] [Full Text] [Related]
9. myd88 signalling is critical in the development of pancreatic cancer cachexia.
Zhu X; Burfeind KG; Michaelis KA; Braun TP; Olson B; Pelz KR; Morgan TK; Marks DL
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):378-390. PubMed ID: 30666818
[TBL] [Abstract] [Full Text] [Related]
10. P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.
de Almeida Chuffa LG; de Moura Ferreira G; Lupi LA; da Silva Nunes I; Fávaro WJ
J Ovarian Res; 2018 Jan; 11(1):8. PubMed ID: 29343281
[TBL] [Abstract] [Full Text] [Related]
11. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
[TBL] [Abstract] [Full Text] [Related]
12. Demographic characteristics of chronic pancreatitis patients in the era of endosonography: Experience of a single tertiary referral center in Turkey.
Şişman G; Köroğlu E; Erzin Y; Hatemi İ; Tuncer M; Şentürk H
Turk J Gastroenterol; 2016 May; 27(3):284-9. PubMed ID: 27210787
[TBL] [Abstract] [Full Text] [Related]
13. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian cancer Stem Cells and Prevents Recurrence In Vivo.
Alvero AB; Heaton A; Lima E; Pitruzzello M; Sumi N; Yang-Hartwich Y; Cardenas C; Steinmacher S; Silasi DA; Brown D; Mor G
Mol Cancer Ther; 2016 Jun; 15(6):1279-90. PubMed ID: 27196760
[TBL] [Abstract] [Full Text] [Related]
14. Targetable genetic features of primary testicular and primary central nervous system lymphomas.
Chapuy B; Roemer MG; Stewart C; Tan Y; Abo RP; Zhang L; Dunford AJ; Meredith DM; Thorner AR; Jordanova ES; Liu G; Feuerhake F; Ducar MD; Illerhaus G; Gusenleitner D; Linden EA; Sun HH; Homer H; Aono M; Pinkus GS; Ligon AH; Ligon KL; Ferry JA; Freeman GJ; van Hummelen P; Golub TR; Getz G; Rodig SJ; de Jong D; Monti S; Shipp MA
Blood; 2016 Feb; 127(7):869-81. PubMed ID: 26702065
[TBL] [Abstract] [Full Text] [Related]
15. MiRNA-149 modulates chemosensitivity of ovarian cancer A2780 cells to paclitaxel by targeting myd88.
Zhan Y; Xiang F; Wu R; Xu J; Ni Z; Jiang J; Kang X
J Ovarian Res; 2015 Jul; 8():48. PubMed ID: 26223974
[TBL] [Abstract] [Full Text] [Related]
16. Novel adjuvants from seaweed impede autophagy signaling in therapy-resistant residual pancreatic cancer.
Aravindan S; Ramraj SK; Somasundaram ST; Aravindan N
J Biomed Sci; 2015 Apr; 22(1):28. PubMed ID: 25898131
[TBL] [Abstract] [Full Text] [Related]
17. Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic cancer by Manipulation of Myeloid Cell Populations.
Sanders KL; Fox BA; Bzik DJ
Cancer Immunol Res; 2015 Aug; 3(8):891-901. PubMed ID: 25804437
[TBL] [Abstract] [Full Text] [Related]
18. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in myd88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract] [Full Text] [Related]
19. A novel serum microRNA panel to discriminate benign from malignant ovarian disease.
Langhe R; Norris L; Saadeh FA; Blackshields G; Varley R; Harrison A; Gleeson N; Spillane C; Martin C; O'Donnell DM; D'Arcy T; O'Leary J; O'Toole S
Cancer Lett; 2015 Jan; 356(2 Pt B):628-36. PubMed ID: 25451316
[TBL] [Abstract] [Full Text] [Related]
20. Myeloid differentiation factor 88 promotes cisplatin chemoresistance in ovarian cancer.
Liu G; Du P; Zhang Z
Cell Biochem Biophys; 2015 Mar; 71(2):963-9. PubMed ID: 25308861
[TBL] [Abstract] [Full Text] [Related]
[Next]
